Herein, we show that IOX1 enabled a paradigm of potent antibody-independent chemo-immunotherapy, where IOX1 effectively downregulated the PD-L1 expression of cancer cells and simultaneously stimulated the DOX-induced ICD through deactivation of the JMJD1A/β-catenin pathway (Fig. 1). Here, KDM3A is linked to cancer.